Methods and applications of non-human primate models of Parkinson's disease based on PARK7 gene loss-of-function.

By using the CRISPR/Cas9 system to target and knock down the PARK7 gene in the substantia nigra of nonhuman primates, an animal model of Parkinson's disease was constructed. This solved the problem that existing models could not simulate neuronal degeneration and α-synuclein accumulation, and achieved efficient model construction and stability.

CN123100565APending Publication Date: 2026-11-17JINAN UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611508084.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-28
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing PARK7 knockout mouse and pig models cannot effectively simulate the pathological features of progressive neuronal degeneration and death and significant α-synuclein accumulation in the brains of Parkinson's disease patients, limiting the search for effective drugs and methods to treat PD.

Method used

By using the CRISPR/Cas9 system to target and knock down the PARK7 gene in the substantia nigra of non-human primates, and by delivering sgRNA and Cas9 nuclease via an adeno-associated virus vector to perform gene editing, the PARK7 gene was rendered nonfunctional, thus establishing an animal model of Parkinson's disease.

Benefits of technology

This study simulates the progressive degeneration of nerve cells in Parkinson's disease, improving the phenotypic consistency and stability of the model, shortening the model construction cycle, reducing experimental costs, and increasing the certainty of gene function disruption.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention belongs to the field of animal disease models, specifically relating to a method and application for constructing a non-human primate model of Parkinson's disease based on PARK7 gene loss of function. This application discovers that DJ-1 loss can cause degeneration and death of dopamine neurons in the substantia nigra of the non-human primate brain, reduced dopamine synthesis in the striatum, and significant accumulation of endogenous α-synuclein to form Lewy bodies. This model can effectively simulate important pathological features of Parkinson's disease patients in non-human primates, providing an important tool for studying the pathogenesis of Parkinson's disease, evaluating drug efficacy, and developing novel treatment strategies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of animal disease models, specifically relating to a method and application for constructing a non-human primate model of Parkinson's disease based on the loss of function of the PARK7 gene. Background Technology

[0002] Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease. Its main pathological features are degenerative changes in dopaminergic neurons in the substantia nigra and striatum, and Lewy bodies formed by the aggregation of misfolded α-synuclein. PD patients clinically present with bradykinesia, muscle rigidity, resting tremor, and gait disturbances. Current treatments for Parkinson's disease can alleviate symptoms to some extent, but they cannot stop the progressive degeneration and death of brain nerve cells, and there remains no cure.

[0003] Genetic mutations can cause Parkinson's disease. The typical pathological features of Parkinson's disease are selective dopamine-induced neuronal death and Lewy bodies formed by the aggregation of α-synuclein. Among these, mutations in the PARK7 gene are a key pathogenic gene for recessive Parkinson's disease. The DJ-1 protein encoded by the PARK7 gene is a member of the ThiJ / PfpI molecular chaperone family; mutations in this protein can cause juvenile Parkinson's disease due to loss of gene function, leading to premature onset and immense suffering for patients. Point mutations and large deletions in the DJ-1 gene are both present in PD patients. However, DJ-1 knockout mouse and pig models cannot effectively mimic the important pathological features of progressive neuronal degeneration and death and significant α-synuclein aggregation in the brains of Parkinson's patients, greatly hindering the clinical translational value of these animal models.

[0004] Non-human primate models are more closely similar to humans in terms of genetics, physiology, and brain structure and function. Furthermore, existing PARK7 knockout mouse and pig models cannot effectively simulate the important pathological features of progressive neuronal degeneration and death and significant α-synuclein accumulation in the brains of Parkinson's disease patients, greatly limiting the search for effective drugs and methods to treat PD. Therefore, establishing an animal model that effectively simulates the important neurodegenerative pathologies of PD patients using non-human primates is of great significance for exploring the pathogenesis of PD and developing therapeutic targets. Summary of the Invention

[0005] To address the above problems, this invention provides a method for constructing an animal model of Parkinson's disease, comprising: using a gene editing system to target and knock down the PARK7 gene in the substantia nigra of a non-human primate brain, thereby causing the PARK7 gene to lose its function.

[0006] Furthermore, the gene editing system is a CRISPR / Cas9 system, and the method includes: co-injecting sgRNA targeting the PARK7 gene and Cas9 nuclease into the substantia nigra of the non-human primate brain.

[0007] Furthermore, the sgRNA targets exon 4 and / or exon 7 of the PARK7 gene.

[0008] Furthermore, the sgRNA comprises sequences as shown in SEQ ID NO.1 and / or SEQ ID NO.2:

[0009] SEQ ID NO.1:GATGTGGTGGTTCTACCAGG;

[0010] SEQ ID NO. 2: ACGGCCTGATTCTTACAAGC.

[0011] Furthermore, the sgRNA and Cas9 nuclease are delivered to the substantia nigra of the non-human primate brain via an adeno-associated virus vector.

[0012] Furthermore, the serotype of the AAV vector is MAC.

[0013] Furthermore, the ratio of sgRNA to Cas9 nuclease in the AAV vector is 1:1 to 1:4.

[0014] Furthermore, the non-human primates are selected from cynomolgus monkeys, rhesus monkeys, or macaques.

[0015] Furthermore, the targeted knockdown is delivered to the substantia nigra of the non-human primate brain via stereotactic injection.

[0016] This invention also provides the application of the Parkinson's disease animal model obtained by the above method in the preparation of models for research on the pathogenesis of Parkinson's disease, drug screening, or validation of treatment strategies.

[0017] The present invention has the following beneficial effects:

[0018] (1) This invention knocks down the PARK7 gene and destroys the endogenous PARK7 gene in the substantia nigra, causing dopaminergic neurons to produce continuous metabolic stress, thereby simulating the progressive degeneration process of nerve cells in Parkinson's disease and overcoming the problem that traditional toxin models can only simulate acute injury and lack genetic basis.

[0019] (2) This invention achieves efficient in vivo knockout of the PARK7 gene by using the adeno-associated virus-mediated CRISPR / Cas9 system to deliver the gene to the substantia nigra region of adult animals, avoiding the developmental compensation effect caused by traditional embryo editing, thereby significantly improving the consistency and stability of the model phenotype.

[0020] (3) This invention performs gene editing by directly delivering the CRISPR / Cas9 system into the brain of adult non-human primates, avoiding the traditional embryo manipulation and breeding screening process, significantly shortening the model construction cycle and reducing experimental costs, while improving the model construction success rate.

[0021] (4) This invention designs sgRNAs that target multiple key exons of the PARK7 gene to achieve gene fragment deletion knockout. Compared with single-site editing, it improves the certainty of gene function destruction and reduces the dependence on single editing efficiency, thereby alleviating the efficiency fluctuation problem of CRISPR / Cas9 system in vivo application to a certain extent. Attached Figure Description

[0022] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0023] Figure 1 Map of AAV-PARK7 sgRNA plasmid;

[0024] Figure 2 DNA verification diagram of PARK7 target sgRNA site for in vitro experiments;

[0025] Figure 3 PARK7 sgRNA recombinant vector virus-mediated DJ-1 deletion leads to decreased dopaminergic synthesis capacity in the brains of young monkeys¹ 8 F-DOPA PET imaging performance;

[0026] Figure 4 The loss of DJ-1 protein caused by PARK7 sgRNA recombinant vector virus can lead to endogenous neurodegenerative death and a reduction in TH neurons in the substantia nigra of young monkey brains (A) (B, C).

[0027] Figure 5 The deletion of DJ-1 protein caused by PARK7 sgRNA recombinant vector virus can lead to significant aggregation of endogenously phosphorylated α-synuclein S129 in the substantia nigra of young monkey brains.

[0028] Figure 6 DJ-1 deletion mediated by the PARK7 sgRNA recombinant vector virus resulted in abnormal motor function in young monkeys. The impact of DJ-1 deletion on the monkey's motor phenotype was evaluated using a treadmill exercise capacity assessment. Detailed Implementation

[0029] Various exemplary embodiments of the present invention are now described in detail. Unless otherwise specified, the methods used in the embodiments are conventional methods, and the reagents used are commercially available reagents or reagents prepared using conventional methods. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, characteristics, and embodiments of the present invention.

[0030] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0031] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0032] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be readily apparent to those skilled in the art. This specification and embodiments are merely exemplary.

[0033] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0034] I. Modification of Recombinant Expression Vectors

[0035] The ssAAV.U6-E4gRNA-U6-E7gRNA(mk PARK7).EFS.ZsGreen (abbreviated as: AAV-PARK7 sgRNA) plasmid used in this embodiment was constructed by Guangzhou Paizhen Biotechnology Co., Ltd. This plasmid carries a Zsgreen fluorescent protein tag initiated by the EFs promoter. A schematic diagram of the viral vector used to construct the expression plasmid is shown below. Figure 1 .

[0036] The AAV-CMV-spCas9 plasmid was previously constructed in our laboratory.

[0037] II. Validation of the effectiveness of the constructed plasmids in 293T and SH-SY5Y cells.

[0038] AAV-PARK7 sgRNA and AAV-CMV-spCas9 were transfected into 293T and SH-SY5Y cells via PolyPlus, while the control group was transfected with the control plasmid. Samples were collected 72 hours later for Western blot validation, and the results are as follows: Figure 2 As shown.

[0039] The specific steps are as follows:

[0040] (1) 293T cells were seeded in 12-well plates one day before transfection, with a seeding density of about 40%-50%; SH-SY5Y cells were seeded in 12-well plates with a seeding density of about 50%-60%.

[0041] (2) Take a sterile EP tube, add 200 µL of jetPRIME Buffer to each well, and add 1 µg of plasmid. Specifically, mix the two plasmids according to the mass ratio of Cas9:gRNA = 3:1. That is, add 0.75 µg AAV-CMV-spCas9 + 0.25 µg AAV-PARK7-sgRNA.

[0042] Mix the DNA mixture using a Vortex vortex for 1-2 seconds, then incubate briefly. Add 2 µL of JetPRIME® reagent (DNA mass to reagent volume ratio of 1:2) to the above DNA mixture, and immediately mix using a Vortex vortex for 10 seconds, then incubate briefly at room temperature for 10-15 minutes. Add the incubated transfection complex dropwise and evenly to the cell culture medium in a 12-well plate, gently shaking the plate back and forth and side to side (in a cross-shaped motion) to distribute the transfection complex evenly, then return it to a 37°C incubator.

[0043] (3) Observe the cell status 24 hours after transfection and replace with fresh complete culture medium. Continue culturing until 72 hours after transfection, and then collect cell DNA samples.

[0044] (4) T7E1 detection

[0045] The T7E1 experimental steps in this embodiment are as follows: The specific primer sequences are shown in Table 1 below. Exons 4 and 7 were amplified by PCR. 3-5 μL of the PCR product was annealed to allow DNA double-strand re-pairing. The PCR program was as follows: 95℃, 10 min; 85℃, 1 min; 75℃, 1 min; 65℃, 1 min; 55℃, 1 min; 45℃, 1 min; 35℃, 1 min; 25℃, 1 min; 4℃, 10 min. Subsequently, T7E1 enzyme was added for digestion (refer to the instruction manual for specific procedures), and the mixture was incubated at 37℃ for 15 min. See the results example below. Figure 2 A.

[0046] (5) Identification of positive results for large fragment deletions

[0047] The identification steps for a large deletion of the PARK7 gene in this embodiment are as follows: PCR primers were designed targeting the upstream and downstream regions of the two gRNA target sites of the PARK7 gene. The specific primer sequences are shown in Table 1 below. Genomic DNA was extracted from gene-edited animals and used as a template for PCR amplification. The PCR amplification program was as follows: denaturation at 95℃ for 10 s, annealing at 60℃ for 15 s, extension at 72℃ for 10 s, repeated several times, and stored at 4℃. See the results example below. Figure 2 B.

[0048] according to Figure 2 The results show that DJ-1 in the cell line can be effectively edited at the DNA level.

[0049] Table 1

[0050] experiment site sequence T7E1 testing Exon 4 F:ACAGGAAGGAGATTATACTACCR:CCTCCTCCCGAAATATTTGAAT T7E1 testing Exon 7 F:TTCCCCGGCACTTCAGAATTR:GGACAGCGACTTCTGAACACAT Large segments missing F:ACAGGAAGGAGATTATACTACCR:GGACAGCGACTTCTGAACAC

[0051] III. Animal Model Construction and Pathological and Imaging Examination

[0052] 1. Virus Packaging

[0053] The constructed viral vectors ssAAV.U6-E4gRNA-U6-E7gRNA(mk PARK7).EFS.ZsGreen and AAV-CMV-Cas9 were packaged with AAV virus, using the MAC serotype. The specific steps are described in Yanget.al., J Clin Invest, 2017 (doi:10.1172 / JCI92087), and injected into the substantia nigra of monkey brain using a stereotactic injection method.

[0054] The AAV vector contains a tandem sequence of ssAAV.U6-E4gRNA-U6-E7gRNA (mk PARK7).EFS.ZsGreen:

[0055] PARK7 T1: 5'-GATGTGGTGGTTCTACCAGG-3'

[0056] PARK7 T2: 5'-ACGGCCTGATTCTTACAAGC-3'

[0057] 2. Virus injection

[0058] The specific injection protocol was based on published papers, including stereotactic localization of the substantia nigra region of the cynomolgus monkey brain using MRI scans, with parameters determined by actual MRI measurements. AAV-Cas9 and AAV-PARK7 sgRNA were mixed at a 3:1 ratio and then injected into the recipient monkey's cortex or substantia nigra via targeted injection. The total viral load injected was 2*10^12 GC in both cases. The control side was injected with AAV control sgRNA-EFs-Zsgreen / AAV Cas9. To avoid individual variability, the brain injection protocol in this example involved injecting AAV control sgRNA-CMV-Zsgreen / AAV Cas9 and AAV-PARK7 sgRNA / AAV Cas9 viruses into the left and right sides of the same animal, respectively.

[0059] 3. Immunostaining and Western blot detection

[0060] To assess the impact of PARK7 deficiency on the dopaminergic nervous system in the substantia nigra of monkey brain, immunofluorescence staining analysis was performed using the neuronal marker NeuN and the dopaminergic neuronal marker tyrosine hydroxylase. Figure 4 As shown, after targeted knockdown of PARK7 in the substantia nigra region of monkey brain, compared with the AAV Control-gRNA control group, the signal of NeuN positive neurons in the PARK7 sgRNA-treated region was significantly reduced, and the marker signal of TH positive dopaminergic neurons was also reduced, suggesting that DJ-1 deficiency can lead to damage to dopaminergic neurons in the substantia nigra.

[0061] Figure 4 A showed that the ZsGreen-labeled PARK7 sgRNA recombinant vector achieved effective transduction in the substantia nigra region. Compared with the Control-gRNA group, the PARK7 sgRNA group had a reduced number of NeuN-positive cells, indicating that PARK7 deficiency affects the survival of substantia nigra neurons. Figure 4B. Western blot analysis showed that DJ-1 protein expression decreased after PARK7 knockout, and TH protein levels also decreased, indicating that DJ-1 deficiency leads to impaired function of dopaminergic neurons in the substantia nigra. Figure 4 Immunohistochemical analysis showed that the number of TH-positive neurons decreased after PARK7 knockout, further supporting the view that DJ-1 deficiency leads to impaired function of dopaminergic neurons in the substantia nigra.

[0062] Immunohistochemical analysis revealed that PARK7 knockdown caused significant pathological accumulation of α-synuclein S129 protein in the substantia nigra of the midbrain and in the monkey cortex (e.g., Figure 5 (As shown). Figure 5 A shows that the ZsGreen-labeled PARK7 sgRNA recombinant vector was effectively transduced in the substantia nigra region. In the ZsGreen-positive region, the pS129-α-syn immunofluorescence signal was significantly enhanced, while no similar changes were observed in the Control-gRNA group, suggesting that DJ-1 deficiency promotes abnormal phosphorylation and pathological accumulation of α-synuclein in the substantia nigra region. Figure 5 B further detected the pS129-α-syn protein level in different monkey brain samples using Western blot. The results showed that pS129-α-syn signal was enhanced after PARK7 sgRNA treatment, which further supports the pathological changes related to abnormal phosphorylation of α-synuclein induced by DJ-1 deletion.

[0063] 4. PET / CT scan

[0064] PET-CT scans were performed at the PET / CT-MRI Center of the First Affiliated Hospital of Jinan University. The PET tracer [18F]DOPA was radiolabeled at the Circulator and PET Radiopharmaceutical Center (CCPR) of Jinan University. Briefly, animals were fasted for 12 hours prior to tracer injection. The average dose of [18F]DOPA injected was 0.5 mCi / kg body weight (18.5 MBq / kg). Animals were placed in the imaging chamber and anesthetized with a 2.0% isoflurane / oxygen mixture throughout the procedure. Body temperature was maintained at 37°C and monitored during anesthesia. Head position was fixed using a stereotactic frame. CT scans were performed first, followed by a 10-minute static positron emission tomography (PET) data collection 60 minutes post-injection. CT data were acquired under breath-hold conditions, modulated using GE AutomA technology at 140 kV, 230 mA, a noise level of 30, a slice thickness of 3.75 mm, an interslice spacing of 3.27 mm, a matrix size of 256 × 256, and a scan FOV of 70 cm. Data analysis was performed using PMOD 4.1 software. [18F] DOPA uptake in the occipital cortex was used as a reference for SUVr analysis. PET images were registered with individual MR images and then converted to brain template MR images. The bilateral striatum was analyzed, regions of interest were plotted and resampled into PET space, and SUVs were extracted using Carimas and PMOD software. SUVs were corrected for the monkeys' initial injection dose and body weight. Normalization of PET imaging analysis was performed using SUVRR / L (SUV of the right striatum / SUV of the left striatum).

[0065] A key pathological feature of Parkinson's disease is the death of dopamine neurons in the substantia nigra, which leads to reduced dopamine synthesis in the striatum and the accumulation of pathological α-synuclein. In this application, PET / CT was used to detect a similar reduction in dopamine synthesis in the striatum of monkeys injected with PARK7 due to PARK7 knockdown. Figure 3 As shown, representative DOPA PET / CT imaging revealed that two months after injection of AAV-PARK7 sgRNA / Cas9 into the ipsilateral substantia nigra of a 6-year-old monkey, dopamine uptake in the striatum was reduced.

[0066] 5. Treadmill Experiment

[0067] To evaluate the effects of PARK7 gene editing on the locomotor function of non-human primates, treadmill exercise tests were conducted before and two months after viral injection. In behavioral assessments, a specialized electric treadmill was used to evaluate the locomotor function of the non-human primates. All animals underwent acclimatization training for 5 days prior to the experiment, with daily training time of 10–15 minutes. The initial training speed was set at 0.5 km / h and gradually increased to 1.5 km / h to ensure stable walking on the treadmill without significant resistance. Formal experiments were conducted before and two months after viral injection. During testing, animals were placed on the treadmill with an initial running speed of 1.0 km / h. The speed was increased by 0.5 km / h every 2 minutes until reaching 3.0 km / h or the maximum testing time of 15 minutes. Throughout the experiment, the animals' movement was continuously recorded using a video system. Figure 6 As shown.

[0068] The results showed that monkeys injected with AAV-Cas9 / PARK7-gRNA exhibited a significant decrease in sustained motor ability. During the test, the animals were more likely to be unable to continuously follow the treadmill and exhibited varying degrees of gait abnormalities.

[0069] Therefore, this application establishes a new PD model that can highly simulate the important pathological features of PD patients by knocking out the PARK7 gene. This is in stark contrast to the previously reported Park7 knockout mouse and pig models that could not simulate the neuronal degeneration and death and pathological α-synuclein accumulation in PD patients. This provides a new model for studying the pathogenesis of PD and developing potential treatments.

[0070] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A method for constructing a model of Parkinson's disease in an animal, characterized by, The method comprises: Targeting and knocking down a PARK7 gene in a substantia nigra of a non-human primate brain by using a gene editing system to make the PARK7 gene function-deficient.

2. The construction method of claim 1, wherein, The gene editing system is a CRISPR / Cas9 system, and the method comprises: co-injecting sgRNA targeting the PARK7 gene and Cas9 nuclease into a substantia nigra site of the non-human primate brain.

3. The construction method of claim 2, wherein, The sgRNA targets the fourth exon and / or the seventh exon of the PARK7 gene.

4. The construction method according to claim 3, characterized in that, The sgRNA comprises a sequence as shown in SEQ ID NO. 1 and / or SEQ ID NO. 2: SEQ ID NO. 1: GATGTGGTGGTTCTACCAGG; SEQ ID NO. 2: ACGGCCTGATTCTTACAAGC.

5. The construction method according to any one of claims 2-4, characterized in that, The sgRNA and Cas9 nuclease are delivered to the substantia nigra site of the non-human primate brain by an adeno-associated virus (AAV) vector.

6. The construction method of claim 5, wherein, The AAV vector is of a MAC type.

7. The construction method according to claim 5 or 6, characterized in that, The sgRNA and Cas9 nuclease in the AAV vector are used in a ratio of 1:1 to 1:

4.

8. The construction method according to any one of claims 1 to 7, characterized in that, The non-human primate is selected from a cynomolgus monkey, a rhesus monkey, or a macaque monkey.

9. The construction method according to any one of claims 1 to 8, characterized in that, The targeting and knocking down are achieved by delivering the gene editing system to the substantia nigra site of the non-human primate brain by stereotactic injection.

10. Use of a Parkinson's disease animal model constructed according to any one of claims 1-9 in the preparation of a model for the study of the pathogenesis of Parkinson's disease, drug screening, or verification of a treatment strategy.